Influence of drug molecules on regulatory B cells.
Identifieur interne : 001562 ( Ncbi/Merge ); précédent : 001561; suivant : 001563Influence of drug molecules on regulatory B cells.
Auteurs : Kahina Amrouche [France] ; Christophe Jamin [France]Source :
- Clinical immunology (Orlando, Fla.) [ 1521-7035 ] ; 2017.
Descripteurs français
- KwdFr :
- Acide mycophénolique (pharmacologie), Animaux, Anticorps monoclonaux humanisés (pharmacologie), Antinéoplasiques (pharmacologie), Cytokines (immunologie), Facteur d'activation des lymphocytes B (immunologie), Hormones corticosurrénaliennes (pharmacologie), Humains, Immunosuppresseurs (pharmacologie), Lymphocytes B régulateurs (), Lymphocytes B régulateurs (immunologie), Méthotrexate (pharmacologie), Pyrroles (pharmacologie), Quinazolines (pharmacologie), Récepteurs de type Toll (immunologie), Récepteurs pour l'antigène des lymphocytes B (immunologie), Sirolimus (pharmacologie), Sémaphorines (pharmacologie), Trétinoïne (pharmacologie), Vitamine D (pharmacologie), Vitamines (pharmacologie).
- MESH :
- immunologie : Cytokines, Facteur d'activation des lymphocytes B, Lymphocytes B régulateurs, Récepteurs de type Toll, Récepteurs pour l'antigène des lymphocytes B.
- pharmacologie : Acide mycophénolique, Anticorps monoclonaux humanisés, Antinéoplasiques, Hormones corticosurrénaliennes, Immunosuppresseurs, Méthotrexate, Pyrroles, Quinazolines, Sirolimus, Sémaphorines, Trétinoïne, Vitamine D, Vitamines.
- Animaux, Humains, Lymphocytes B régulateurs.
English descriptors
- KwdEn :
- Adrenal Cortex Hormones (pharmacology), Animals, Antibodies, Monoclonal, Humanized (pharmacology), Antineoplastic Agents (pharmacology), B-Cell Activating Factor (immunology), B-Lymphocytes, Regulatory (drug effects), B-Lymphocytes, Regulatory (immunology), CD40 Antigens (immunology), Cytokines (immunology), Humans, Immunosuppressive Agents (pharmacology), Methotrexate (pharmacology), Mycophenolic Acid (pharmacology), Pyrroles (pharmacology), Quinazolines (pharmacology), Receptors, Antigen, B-Cell (immunology), Semaphorins (pharmacology), Sirolimus (pharmacology), Toll-Like Receptors (immunology), Tretinoin (pharmacology), Vitamin D (pharmacology), Vitamins (pharmacology).
- MESH :
- chemical , immunology : B-Cell Activating Factor, CD40 Antigens, Cytokines, Receptors, Antigen, B-Cell, Toll-Like Receptors.
- chemical , pharmacology : Adrenal Cortex Hormones, Antibodies, Monoclonal, Humanized, Antineoplastic Agents, Immunosuppressive Agents, Methotrexate, Mycophenolic Acid, Pyrroles, Quinazolines, Semaphorins, Sirolimus, Tretinoin, Vitamin D, Vitamins.
- drug effects : B-Lymphocytes, Regulatory.
- immunology : B-Lymphocytes, Regulatory.
- Animals, Humans.
Abstract
By their suppressive functions, regulatory B (Breg) cells are considered as key elements in the control and development of various disease states. Many signals can induce Bregs in vivo and in vitro and often from heterogeneous populations. Several specific signals delivered in a timely immunological context contribute to the establishment of Bregs. These are endogenous and physiological signals or stimuli, widely discussed in the literature participating in the establishment of an effective immune response. However, exogenous signals, much less clearly identified can also be considered as Bregs inducers. These extrinsic signals are capable of directly or indirectly influencing the suppressive capacity of Bregs, but also their expansion and functional restoration in its absence. Faced with the excitement generated by the development of processes favoring the expansion of Bregs in mice for therapeutic purposes, the challenge today is to extrapolate such approaches in humans. This perspective may already be in effect.
DOI: 10.1016/j.clim.2017.04.011
PubMed: 28461109
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 000B58
- to stream PubMed, to step Curation: 000B58
- to stream PubMed, to step Checkpoint: 000B32
Links to Exploration step
pubmed:28461109Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Influence of drug molecules on regulatory B cells.</title><author><name sortKey="Amrouche, Kahina" sort="Amrouche, Kahina" uniqKey="Amrouche K" first="Kahina" last="Amrouche">Kahina Amrouche</name><affiliation wicri:level="3"><nlm:affiliation>UMR 1227, Lymphocytes B et Autoimmunité, Université de Brest, INSERM, Brest, France; LabEx IGO "Immunotherapy, Graft, Oncology", Brest, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>UMR 1227, Lymphocytes B et Autoimmunité, Université de Brest, INSERM, Brest, France; LabEx IGO "Immunotherapy, Graft, Oncology", Brest</wicri:regionArea><placeName><region type="region">Région Bretagne</region><region type="old region">Région Bretagne</region><settlement type="city">Brest</settlement></placeName></affiliation></author><author><name sortKey="Jamin, Christophe" sort="Jamin, Christophe" uniqKey="Jamin C" first="Christophe" last="Jamin">Christophe Jamin</name><affiliation wicri:level="3"><nlm:affiliation>UMR 1227, Lymphocytes B et Autoimmunité, Université de Brest, INSERM, Brest, France; LabEx IGO "Immunotherapy, Graft, Oncology", Brest, France; Laboratoire d'Immunologie et Immunothérapie, CHRU Morvan, Brest, France. Electronic address: christophe.jamin@univ-brest.fr.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>UMR 1227, Lymphocytes B et Autoimmunité, Université de Brest, INSERM, Brest, France; LabEx IGO "Immunotherapy, Graft, Oncology", Brest, France; Laboratoire d'Immunologie et Immunothérapie, CHRU Morvan, Brest</wicri:regionArea><placeName><region type="region">Région Bretagne</region><region type="old region">Région Bretagne</region><settlement type="city">Brest</settlement></placeName></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2017">2017</date><idno type="RBID">pubmed:28461109</idno><idno type="pmid">28461109</idno><idno type="doi">10.1016/j.clim.2017.04.011</idno><idno type="wicri:Area/PubMed/Corpus">000B58</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000B58</idno><idno type="wicri:Area/PubMed/Curation">000B58</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000B58</idno><idno type="wicri:Area/PubMed/Checkpoint">000B32</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000B32</idno><idno type="wicri:Area/Ncbi/Merge">001562</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Influence of drug molecules on regulatory B cells.</title><author><name sortKey="Amrouche, Kahina" sort="Amrouche, Kahina" uniqKey="Amrouche K" first="Kahina" last="Amrouche">Kahina Amrouche</name><affiliation wicri:level="3"><nlm:affiliation>UMR 1227, Lymphocytes B et Autoimmunité, Université de Brest, INSERM, Brest, France; LabEx IGO "Immunotherapy, Graft, Oncology", Brest, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>UMR 1227, Lymphocytes B et Autoimmunité, Université de Brest, INSERM, Brest, France; LabEx IGO "Immunotherapy, Graft, Oncology", Brest</wicri:regionArea><placeName><region type="region">Région Bretagne</region><region type="old region">Région Bretagne</region><settlement type="city">Brest</settlement></placeName></affiliation></author><author><name sortKey="Jamin, Christophe" sort="Jamin, Christophe" uniqKey="Jamin C" first="Christophe" last="Jamin">Christophe Jamin</name><affiliation wicri:level="3"><nlm:affiliation>UMR 1227, Lymphocytes B et Autoimmunité, Université de Brest, INSERM, Brest, France; LabEx IGO "Immunotherapy, Graft, Oncology", Brest, France; Laboratoire d'Immunologie et Immunothérapie, CHRU Morvan, Brest, France. Electronic address: christophe.jamin@univ-brest.fr.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>UMR 1227, Lymphocytes B et Autoimmunité, Université de Brest, INSERM, Brest, France; LabEx IGO "Immunotherapy, Graft, Oncology", Brest, France; Laboratoire d'Immunologie et Immunothérapie, CHRU Morvan, Brest</wicri:regionArea><placeName><region type="region">Région Bretagne</region><region type="old region">Région Bretagne</region><settlement type="city">Brest</settlement></placeName></affiliation></author></analytic><series><title level="j">Clinical immunology (Orlando, Fla.)</title><idno type="eISSN">1521-7035</idno><imprint><date when="2017" type="published">2017</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adrenal Cortex Hormones (pharmacology)</term><term>Animals</term><term>Antibodies, Monoclonal, Humanized (pharmacology)</term><term>Antineoplastic Agents (pharmacology)</term><term>B-Cell Activating Factor (immunology)</term><term>B-Lymphocytes, Regulatory (drug effects)</term><term>B-Lymphocytes, Regulatory (immunology)</term><term>CD40 Antigens (immunology)</term><term>Cytokines (immunology)</term><term>Humans</term><term>Immunosuppressive Agents (pharmacology)</term><term>Methotrexate (pharmacology)</term><term>Mycophenolic Acid (pharmacology)</term><term>Pyrroles (pharmacology)</term><term>Quinazolines (pharmacology)</term><term>Receptors, Antigen, B-Cell (immunology)</term><term>Semaphorins (pharmacology)</term><term>Sirolimus (pharmacology)</term><term>Toll-Like Receptors (immunology)</term><term>Tretinoin (pharmacology)</term><term>Vitamin D (pharmacology)</term><term>Vitamins (pharmacology)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Acide mycophénolique (pharmacologie)</term><term>Animaux</term><term>Anticorps monoclonaux humanisés (pharmacologie)</term><term>Antinéoplasiques (pharmacologie)</term><term>Cytokines (immunologie)</term><term>Facteur d'activation des lymphocytes B (immunologie)</term><term>Hormones corticosurrénaliennes (pharmacologie)</term><term>Humains</term><term>Immunosuppresseurs (pharmacologie)</term><term>Lymphocytes B régulateurs ()</term><term>Lymphocytes B régulateurs (immunologie)</term><term>Méthotrexate (pharmacologie)</term><term>Pyrroles (pharmacologie)</term><term>Quinazolines (pharmacologie)</term><term>Récepteurs de type Toll (immunologie)</term><term>Récepteurs pour l'antigène des lymphocytes B (immunologie)</term><term>Sirolimus (pharmacologie)</term><term>Sémaphorines (pharmacologie)</term><term>Trétinoïne (pharmacologie)</term><term>Vitamine D (pharmacologie)</term><term>Vitamines (pharmacologie)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="immunology" xml:lang="en"><term>B-Cell Activating Factor</term><term>CD40 Antigens</term><term>Cytokines</term><term>Receptors, Antigen, B-Cell</term><term>Toll-Like Receptors</term></keywords><keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Adrenal Cortex Hormones</term><term>Antibodies, Monoclonal, Humanized</term><term>Antineoplastic Agents</term><term>Immunosuppressive Agents</term><term>Methotrexate</term><term>Mycophenolic Acid</term><term>Pyrroles</term><term>Quinazolines</term><term>Semaphorins</term><term>Sirolimus</term><term>Tretinoin</term><term>Vitamin D</term><term>Vitamins</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>B-Lymphocytes, Regulatory</term></keywords><keywords scheme="MESH" qualifier="immunologie" xml:lang="fr"><term>Cytokines</term><term>Facteur d'activation des lymphocytes B</term><term>Lymphocytes B régulateurs</term><term>Récepteurs de type Toll</term><term>Récepteurs pour l'antigène des lymphocytes B</term></keywords><keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>B-Lymphocytes, Regulatory</term></keywords><keywords scheme="MESH" qualifier="pharmacologie" xml:lang="fr"><term>Acide mycophénolique</term><term>Anticorps monoclonaux humanisés</term><term>Antinéoplasiques</term><term>Hormones corticosurrénaliennes</term><term>Immunosuppresseurs</term><term>Méthotrexate</term><term>Pyrroles</term><term>Quinazolines</term><term>Sirolimus</term><term>Sémaphorines</term><term>Trétinoïne</term><term>Vitamine D</term><term>Vitamines</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Animals</term><term>Humans</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Animaux</term><term>Humains</term><term>Lymphocytes B régulateurs</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">By their suppressive functions, regulatory B (Breg) cells are considered as key elements in the control and development of various disease states. Many signals can induce Bregs in vivo and in vitro and often from heterogeneous populations. Several specific signals delivered in a timely immunological context contribute to the establishment of Bregs. These are endogenous and physiological signals or stimuli, widely discussed in the literature participating in the establishment of an effective immune response. However, exogenous signals, much less clearly identified can also be considered as Bregs inducers. These extrinsic signals are capable of directly or indirectly influencing the suppressive capacity of Bregs, but also their expansion and functional restoration in its absence. Faced with the excitement generated by the development of processes favoring the expansion of Bregs in mice for therapeutic purposes, the challenge today is to extrapolate such approaches in humans. This perspective may already be in effect.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">28461109</PMID><DateCompleted><Year>2017</Year><Month>11</Month><Day>16</Day></DateCompleted><DateRevised><Year>2018</Year><Month>02</Month><Day>06</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1521-7035</ISSN><JournalIssue CitedMedium="Internet"><Volume>184</Volume><PubDate><Year>2017</Year><Month>11</Month></PubDate></JournalIssue><Title>Clinical immunology (Orlando, Fla.)</Title><ISOAbbreviation>Clin. Immunol.</ISOAbbreviation></Journal><ArticleTitle>Influence of drug molecules on regulatory B cells.</ArticleTitle><Pagination><MedlinePgn>1-10</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">S1521-6616(16)30635-0</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.clim.2017.04.011</ELocationID><Abstract><AbstractText>By their suppressive functions, regulatory B (Breg) cells are considered as key elements in the control and development of various disease states. Many signals can induce Bregs in vivo and in vitro and often from heterogeneous populations. Several specific signals delivered in a timely immunological context contribute to the establishment of Bregs. These are endogenous and physiological signals or stimuli, widely discussed in the literature participating in the establishment of an effective immune response. However, exogenous signals, much less clearly identified can also be considered as Bregs inducers. These extrinsic signals are capable of directly or indirectly influencing the suppressive capacity of Bregs, but also their expansion and functional restoration in its absence. Faced with the excitement generated by the development of processes favoring the expansion of Bregs in mice for therapeutic purposes, the challenge today is to extrapolate such approaches in humans. This perspective may already be in effect.</AbstractText><CopyrightInformation>Copyright © 2017 Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Amrouche</LastName><ForeName>Kahina</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>UMR 1227, Lymphocytes B et Autoimmunité, Université de Brest, INSERM, Brest, France; LabEx IGO "Immunotherapy, Graft, Oncology", Brest, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jamin</LastName><ForeName>Christophe</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>UMR 1227, Lymphocytes B et Autoimmunité, Université de Brest, INSERM, Brest, France; LabEx IGO "Immunotherapy, Graft, Oncology", Brest, France; Laboratoire d'Immunologie et Immunothérapie, CHRU Morvan, Brest, France. Electronic address: christophe.jamin@univ-brest.fr.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2017</Year><Month>04</Month><Day>28</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Clin Immunol</MedlineTA><NlmUniqueID>100883537</NlmUniqueID><ISSNLinking>1521-6616</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000305">Adrenal Cortex Hormones</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D061067">Antibodies, Monoclonal, Humanized</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000970">Antineoplastic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053264">B-Cell Activating Factor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D019013">CD40 Antigens</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016207">Cytokines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007166">Immunosuppressive Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011758">Pyrroles</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011799">Quinazolines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011947">Receptors, Antigen, B-Cell</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D039961">Semaphorins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D051193">Toll-Like Receptors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014815">Vitamins</NameOfSubstance></Chemical><Chemical><RegistryNumber>1406-16-2</RegistryNumber><NameOfSubstance UI="D014807">Vitamin D</NameOfSubstance></Chemical><Chemical><RegistryNumber>5688UTC01R</RegistryNumber><NameOfSubstance UI="D014212">Tretinoin</NameOfSubstance></Chemical><Chemical><RegistryNumber>7I279E1NZ8</RegistryNumber><NameOfSubstance UI="C543528">sotrastaurin</NameOfSubstance></Chemical><Chemical><RegistryNumber>HU9DX48N0T</RegistryNumber><NameOfSubstance UI="D009173">Mycophenolic Acid</NameOfSubstance></Chemical><Chemical><RegistryNumber>I031V2H011</RegistryNumber><NameOfSubstance UI="C502936">tocilizumab</NameOfSubstance></Chemical><Chemical><RegistryNumber>W36ZG6FT64</RegistryNumber><NameOfSubstance UI="D020123">Sirolimus</NameOfSubstance></Chemical><Chemical><RegistryNumber>YL5FZ2Y5U1</RegistryNumber><NameOfSubstance UI="D008727">Methotrexate</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000305" MajorTopicYN="N">Adrenal Cortex Hormones</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D061067" MajorTopicYN="N">Antibodies, Monoclonal, Humanized</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000970" MajorTopicYN="N">Antineoplastic Agents</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053264" MajorTopicYN="N">B-Cell Activating Factor</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D060151" MajorTopicYN="N">B-Lymphocytes, Regulatory</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019013" MajorTopicYN="N">CD40 Antigens</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016207" MajorTopicYN="N">Cytokines</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007166" MajorTopicYN="N">Immunosuppressive Agents</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008727" MajorTopicYN="N">Methotrexate</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009173" MajorTopicYN="N">Mycophenolic Acid</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011758" MajorTopicYN="N">Pyrroles</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011799" MajorTopicYN="N">Quinazolines</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011947" MajorTopicYN="N">Receptors, Antigen, B-Cell</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D039961" MajorTopicYN="N">Semaphorins</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020123" MajorTopicYN="N">Sirolimus</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051193" MajorTopicYN="N">Toll-Like Receptors</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014212" MajorTopicYN="N">Tretinoin</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014807" MajorTopicYN="N">Vitamin D</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014815" MajorTopicYN="N">Vitamins</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="Y">Activation</Keyword><Keyword MajorTopicYN="Y">Control</Keyword><Keyword MajorTopicYN="Y">Drug</Keyword><Keyword MajorTopicYN="Y">Immunotherapy</Keyword><Keyword MajorTopicYN="Y">Regulatory B cells</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2016</Year><Month>11</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2017</Year><Month>04</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>5</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>11</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>5</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">28461109</ArticleId><ArticleId IdType="pii">S1521-6616(16)30635-0</ArticleId><ArticleId IdType="doi">10.1016/j.clim.2017.04.011</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>France</li></country><region><li>Région Bretagne</li></region><settlement><li>Brest</li></settlement></list><tree><country name="France"><region name="Région Bretagne"><name sortKey="Amrouche, Kahina" sort="Amrouche, Kahina" uniqKey="Amrouche K" first="Kahina" last="Amrouche">Kahina Amrouche</name></region><name sortKey="Jamin, Christophe" sort="Jamin, Christophe" uniqKey="Jamin C" first="Christophe" last="Jamin">Christophe Jamin</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/TocilizumabV1/Data/Ncbi/Merge
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001562 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd -nk 001562 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= TocilizumabV1
|flux= Ncbi
|étape= Merge
|type= RBID
|clé= pubmed:28461109
|texte= Influence of drug molecules on regulatory B cells.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/RBID.i -Sk "pubmed:28461109" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd \
| NlmPubMed2Wicri -a TocilizumabV1
| This area was generated with Dilib version V0.6.34. |  |